Shares of Alembic Pharmaceuticals Ltd. are likely to remain in focus after the company announced that it has received final approval from the US Food and Drug Administration (USFDA) for its Tretinoin Cream USP, 0.05%.
The approval marks another addition to Alembic's growing portfolio of products in the United States, strengthening its presence in the world's largest pharmaceutical market. The company disclosed the development through a regulatory filing with stock exchanges on June 12.
Alembic Pharmaceuticals said the USFDA has granted final approval for its Abbreviated New Drug Application (ANDA) for Tretinoin Cream USP, 0.05%.
The approved product is therapeutically equivalent to Retin-A Cream, 0.05%, marketed by Bausch Health US LLC. Tretinoin cream is widely prescribed for the topical treatment of acne vulgaris and is among the commonly used dermatology products in the US market.
The approval enables Alembic to market the product in the United States, further expanding its dermatology portfolio and generic offerings.
According to IQVIA data cited by the company, Tretinoin Cream USP, 0.05%, had an estimated market size of approximately $76 million for the 12 months ended March 2026.
The launch could provide Alembic with an opportunity to strengthen its revenue stream from the US generics business, although the eventual contribution will depend on market competition, pricing dynamics, and product uptake.
USFDA approvals are closely monitored by investors as they enhance the commercialization pipeline of pharmaceutical companies and create new growth avenues in regulated markets.
Following this approval, Alembic Pharmaceuticals now has a cumulative total of 242 ANDA approvals from the USFDA, comprising 222 final approvals and 20 tentative approvals.
The company, which has been operating in the healthcare sector since 1907, continues to focus on expanding its global generics business through research, development, and regulatory filings.
The latest USFDA approval for Tretinoin Cream strengthens Alembic Pharmaceuticals' US product portfolio and provides access to a market estimated at $76 million annually. While investors will await commercialization details and potential revenue contributions, the regulatory milestone is expected to keep Alembic Pharma share price in focus in the near term.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: Jun 12, 2026, 2:01 PM IST
We're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
